New data suggest the frequency of damage and repair processes correlates with disease severity and disability in multiple ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior year period. The increase in research and development expense was primarily ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines ...

While it’s not shocking that sound, vibration, and frequency have the potential to heal given the ... those new to sound bath ...

The therapy's developer ... so maybe because it's more proximal to rods and cones, maybe there's some frequency sensitivity." Trial Background, Results RP comprises a group of rare eye diseases ...

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development. New investor Bedford Ridge Capital and existing ...

LOS ANGELES--(BUSINESS WIRE)--Terray Therapeutics, a biotechnology company improving human health by transforming the speed, cost, and success rate of small molecule drug development using ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...